Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology. For more information, visit scorpiontx.com.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $420M
Founded date: 2020
Investors 7
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.07.2024 | Series C | $150M | - |
| 07.01.2021 | Series B | $162M | - |
| 29.10.2020 | - | $108M | Vida Ventu... |
Mentions in press and media 28
| Date | Title | Description |
| 08.10.2024 | Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Met... | PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOS... |
| 14.08.2024 | The Pulse of Investment: July's Landscape in U.S. Venture Capital | July 2024 was a month of simmering activity in the U.S. venture capital scene. The heat of summer didn’t deter investors, but it did reveal a stark contrast in engagement levels among the major players. While some firms basked in the sun of... |
| 12.08.2024 | Most-Active US Investors In July: Andreessen Horowitz Led Cool Month | 5 Shares Email Facebook Twitter LinkedIn This is a monthly feature that runs down some of the most-active investors in U.S.-based companies, looks at some of their most interesting investments, and includes some odds and ends of who spent w... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 19.07.2024 | The Week’s 10 Biggest Funding Rounds: Cardurion Pharmaceuticals And Human Interest Nab Largest Raises | 5 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 16.07.2024 | Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline | As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel. The Boston-based biotech applies its drug-hunting platform to validated oncogenes to create sm... |
| 16.07.2024 | Scorpion Therapeutics Raises $150M in Series C Financing | Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding. The round was led by Frazier Life Sciences and Lightspeed Venture Partners, and included additional new support from Willet Advisor... |
| 10.10.2023 | Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced... | -- STX-721 is characterized by high selectivity and a potentially best-in-class profile -- -- Scorpion's second program to enter clinical development this year -- -- One of two EGFR programs being developed with Pierre Fabre Laboratories --... |
| 08.01.2021 | Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology | Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
Show more